LONGEVITY & CELLULAR HEALTH / FAQ
Questions From the Numbers
Direct, citation-anchored answers to the questions readers most often bring to NAD+ and MOTS-c research.
What is NAD supplement used for?
In a research context, NAD+ precursor supplements (primarily NMN and NR) are studied for their ability to raise blood NAD+ levels, which fall with age [4][6]. Proposed uses in the published literature include improving metabolic function, insulin sensitivity, and physical capacity. A multicenter human RCT found that oral NMN raised blood NAD+ dose-dependently and improved walking distance over 60 days [2]. A separate trial found NMN improved muscle insulin sensitivity in prediabetic postmenopausal women [3]. However, a 2025 Nature Metabolism review concluded that human efficacy data remain limited for hard clinical endpoints beyond blood NAD+ elevation — the supplement category claims are ahead of the outcome-trial evidence [1]. This site does not recommend any supplement use.
What is the downside of taking NAD+?
Several documented concerns appear in the literature. Oral NAD+ capsules are not well absorbed intact by cells; most researchers consider NMN or NR the rational approach and view plain "NAD+" capsules as likely ineffective. For IV NAD+ therapy, infusions run too fast cause chest discomfort, flushing, and nausea, and a compounded injectable NAD+ was subject to a Class I FDA recall for bacterial endotoxin contamination. A theoretical concern exists that elevated NAD+ could support the metabolism of existing cancer cells. NMN's regulatory status as a dietary supplement has been challenged by the FDA. Perhaps most importantly, raising blood NAD+ is robustly demonstrated, but the translation to longevity or disease prevention in humans is not yet established; the 2025 review calls this out explicitly [1].
Is it safe to take NAD daily?
Within the clinical-trial window, oral NMN and NR are well tolerated at doses up to 1,000 mg/day over study periods of 8-10 weeks, with no significant adverse events in controlled placebo-matched trials [2][5]. That record is reassuring but limited in duration — long-term safety data beyond several months in humans are sparse. The 2025 Nature Metabolism review does not flag specific harm signals in the oral precursor trials but underscores that the human evidence base is still thin and systematic [1]. This site does not advise on daily use, schedule, or dose.
Does NAD cause weight gain?
No published controlled human trial has reported weight gain as an outcome from NAD+ precursor supplementation. The NMN muscle-insulin-sensitivity trial found no change in body composition or HbA1c over 10 weeks [3], and the NR dose-response trial found NR did not elevate LDL cholesterol or disrupt 1-carbon metabolism [5]. The mechanistic story runs in the opposite direction — sirtuin and AMPK activation are generally associated with improved metabolic flexibility — but the evidence does not demonstrate weight loss as a consistent human outcome either. Nothing on this desk constitutes dietary advice.
What does the MOTS-c peptide do?
In animal models, MOTS-c is a mitochondrially encoded signaling peptide that activates AMPK (the cell's master energy sensor) via interference with the folate cycle and de-novo purine biosynthesis, improving glucose uptake and insulin sensitivity primarily in skeletal muscle [10]. Under metabolic stress it translocates from the mitochondrion to the nucleus, where it regulates antioxidant and metabolic genes via the transcription factor NRF2 [12]. In aged mice, exogenous MOTS-c significantly increased treadmill capacity, grip strength, and gait [11], and a 2024 study identified casein kinase 2 (CK2) as a direct binding target [8]. In humans, lower circulating MOTS-c was associated with higher mortality and cardiovascular risk in a hemodialysis cohort [9]. There are no human interventional efficacy trials.
What are the negative side effects of MOTS-c?
No human clinical trials of exogenous MOTS-c have been published, so a validated human side-effect profile does not exist. The cautions drawn from the research literature are structural rather than clinical: MOTS-c is not approved for human use, product purity from research-chemical suppliers is unverified, and rodent doses used in published studies (0.5-15 mg/kg/day) cannot be extrapolated to humans [10]. A mitochondrial DNA variant (m.1382A>C) at the MOTS-c locus has been associated with increased diabetes risk, suggesting that the effects of MOTS-c are not uniform across all individuals. MOTS-c is prohibited in sport by anti-doping authorities including WADA. This site does not advise on use.
Is MOTS-c legal to buy?
In most jurisdictions, MOTS-c can be purchased legally as a research chemical for laboratory use — it is not a controlled substance under typical drug-scheduling laws. However, several important caveats apply. It is prohibited at all times under anti-doping rules (WADA/USADA), so any use by an athlete in a tested sport is a rule violation regardless of purchase legality. It has no approved drug status in any country, meaning it is not legally regulated for human use. Product identity, purity, and sterility are not subject to pharmaceutical oversight. Laws vary by jurisdiction; this desk does not constitute legal advice [10].
How often do you inject MOTS-c?
This desk does not provide dosing guidance, injection schedules, or protocols for any compound. There is no published human pharmacokinetic data for MOTS-c — no measured half-life, bioavailability, or dose-response in humans — so any injection schedule circulating in lay communities has no peer-reviewed foundation [10]. Published animal studies used administration frequencies ranging from daily to every-three-day injection, at doses of 0.5-15 mg/kg, in rodents. Those figures cannot be extrapolated to humans. Readers interested in a health concern should consult a licensed clinician operating with evidence-based, regulated options.
Are NAD+ and MOTS-c related?
They share a common theme — mitochondrial biology and metabolic aging — but are mechanistically distinct. NAD+ is a coenzyme that both carries electrons in energy metabolism and fuels sirtuin-dependent gene regulation; its decline with age is driven by the rising enzyme CD38 [6]. MOTS-c is a peptide encoded within the mitochondrial genome that activates AMPK via an independent route (folate-cycle inhibition) and can travel to the nucleus to regulate stress-responsive genes [12]. Both point toward the same organelle as a central driver of aging biology, but the molecules themselves, their mechanisms, and their evidence bases are entirely different. See the comparison page for a structured head-to-head.
Why does this desk cover both a coenzyme and a peptide together?
The organizing principle of this desk is the cellular-energetics frame: both NAD+ and MOTS-c are molecules that the research literature links to mitochondrial health and metabolic aging, and both are studied in the context of how cells respond to the energy-stress of aging. NAD+ is the metabolic substrate whose decline is a defining feature of aging metabolism [4]; MOTS-c is a mitochondrially encoded signal whose levels track with physical decline [11]. Covering them together on one desk lets a reader see complementary angles on the same question — what goes wrong in the aging cell's energy machinery, and what might be done about it — without having to read two separate sites.